Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 3 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 2 hours agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 19 hours agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 2 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 1 day agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque psoriasis& ...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 2 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
AbbVie (NYSE:ABBV) Shares Up 0%
ETF DAILY NEWS· 6 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0% during mid-day trading on Thursday . The company traded as high as $166.45 and last traded at $166.15. ABBV has been the topic ...
Beese Fulmer Investment Management Inc. Sells 137 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 1 day agoBeese Fulmer Investment Management Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.6% during the first quarter, according to the company in its most recent 13F filing with ...